| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/03/2005 | US20050026898 Semi-solid systems containing azetidine derivatives |
| 02/03/2005 | US20050026867 Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain |
| 02/03/2005 | US20050026864 Bisphosphonate conjugates and methods of making and using the same |
| 02/03/2005 | US20050026859 Methods and compositions of gene delivery agents for systemic and local therapy |
| 02/03/2005 | US20050026858 Modified nucleotides for immunotherapy; induce immunology response; consisting of nucleoside methylphosphonate and 2'-O-methyl-ribonucleoside groups |
| 02/03/2005 | US20050026856 A biological drug conjugates for binding human lupus anti-dsDNA autoantibodies; antibody inhibitor; conjugated with carbohydrates, drugs, lipids, lipopolysaccharides, peptides, proteins, glycoproteins, single-stranded or double-stranded oligonucleotides, haptens |
| 02/03/2005 | US20050026851 Single dose fast dissolving azithromycin |
| 02/03/2005 | US20050026849 Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases |
| 02/03/2005 | US20050026840 Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or pertidomimetics |
| 02/03/2005 | US20050026834 Methods for making proteins containing free cysteine residues |
| 02/03/2005 | US20050026820 reducing nephrotoxicity; increased therapeutic window for the glycopeptide to allow a greater amount to be administered |
| 02/03/2005 | US20050026817 peptide nucleic acids used as gene expression inhibitors and as probes for detection of nucleic acids |
| 02/03/2005 | US20050026816 modified via polyoxyethylene glycol; improved stability to autooxidation; blood substitutes |
| 02/03/2005 | US20050026815 administering to mammals genetic engineered glycoproteins for therapy of autoimmune disease selected from Addison's disease, Crohn's disease, Graves' disease, psoriasis, scleroderma, ulcerative colitis, or aquired immune deficiency syndrome |
| 02/03/2005 | US20050026305 Aminodextran compositions and conjugates and method of making and using them |
| 02/03/2005 | US20050026287 Formulation of stabilized cationic transfection agent (s) /nucleic acid particles |
| 02/03/2005 | US20050026242 Method of complexing a protein by the use of a dispersed system and proteins thereof |
| 02/03/2005 | US20050026229 Cell line for use in generating monoclonal antibodies specific for prostate stem cell antigen (PSCA) for use in diagnosis of cell proliferative disorders; immunodiagnostics |
| 02/03/2005 | US20050026223 Identifying modulators which bind hormone receptors, enhance bone characteristics and treat bone disorders |
| 02/03/2005 | US20050025971 Inorganic reaction product containing iron oxide and transition metal oxide |
| 02/03/2005 | US20050025969 Suspension of magnetic particles in liquid; adding a gold compound; mixing with reducing agents |
| 02/03/2005 | US20050025957 Mixture of glycosides, polyhydroxystearate and glucan; disposable wipes |
| 02/03/2005 | US20050025847 For preventing sexually transmitted disease (STD) infections which includes bisabolol; STDs such as HIV, herpes, gonorrhea, chlamydia, syphilis, and trichomoniasis |
| 02/03/2005 | US20050025846 Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same |
| 02/03/2005 | US20050025828 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| 02/03/2005 | US20050025826 Desolventizing a mixture of a bioactive peptide or salt thereof in an organic solvent, a biodegradable polymer, and hydroxynaphthoic acid or a salt; hydroxynaphthoate salt of a bioactive peptide |
| 02/03/2005 | US20050025823 Methods of use of herbal compositions |
| 02/03/2005 | US20050025821 Lipid-comprising drug delivery complexes and methods for their production |
| 02/03/2005 | US20050025815 Protonated/acidified nucleic acids are effective as bactericidal and/or bacteriostatic agents |
| 02/03/2005 | US20050025812 Salad dressing with weight loss supplement |
| 02/03/2005 | US20050025809 Biodegradable composition for controlled release |
| 02/03/2005 | US20050025807 Cured porous calcium phosphate material and uses thereof |
| 02/03/2005 | US20050025806 A silicone support of methylvinylsiloxane polymer including a fumed silca reinforcement filler; growth and/or reproduction-associated drug, derivative or analogue and carrier; each implant of insufficient size and/or payload for the predetermined threshold blood level of indicated drug; high-speed |
| 02/03/2005 | US20050025794 Film-forming compositions and methods |
| 02/03/2005 | US20050025792 Amphiphilic surfactant with hydrophilic character that is a glyceride polyoxyethylene glycol and saturated fatty acids; or polyoxyethylated hydrogenated castor oil (Cremophor") |
| 02/03/2005 | US20050025791 Pharmaceutical compositions with improved dissolution |
| 02/03/2005 | US20050025788 Systemic delivery of non-viral vector expressing SARS viral genomic vaccine |
| 02/03/2005 | US20050025771 Antitumor agents comprising a targeting portion and an immune response triggering portion |
| 02/03/2005 | US20050025756 Combination with a solvent, skin buffer and antioxidant to improve solubility and bioavailability for a variety of dosage forms |
| 02/03/2005 | US20050025748 Delivery of compounds with rehydrated blood cells |
| 02/03/2005 | US20050025740 Polyoxime compounds and their preparation |
| 02/03/2005 | US20050025717 Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
| 02/03/2005 | US20050025712 Transmucosal absorption through oral mucosa to systemic circulatory system; bioavailability, rapid onset; active ingredient, solvent and low molecular weight hydrocarbon propellant |
| 02/03/2005 | US20050025707 Fumed silica embolic compositions |
| 02/03/2005 | US20050023386 Laboratory scale milling process |
| 02/03/2005 | DE10331439B3 Magnetische Nanopartikel mit verbesserten Magneteigenschaften Magnetic nanoparticles with improved magnetic properties |
| 02/03/2005 | DE10130504B4 Xanthin- und Phenazon-Acesulfam-H-Komplexe mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung Xanthine-phenazone and acesulfame-H-complexes with improved taste, process for their preparation and their use |
| 02/03/2005 | CA2541373A1 Topical skin care composition containing refined peanut oil |
| 02/03/2005 | CA2533849A1 Aminated complex-type sugar chain derivatives and process for the production thereof |
| 02/03/2005 | CA2533101A1 Dispersible formulation of an anti-inflammatory agent |
| 02/03/2005 | CA2532430A1 Humanized versions of monoclonal antibody ds6 that bind tumour antigen ca6 |
| 02/03/2005 | CA2532394A1 Rg1 antibodies and uses thereof |
| 02/03/2005 | CA2532302A1 Method for the preparation of controlled release formulations |
| 02/03/2005 | CA2532035A1 Fugetactic proteins, compositions and methods of use |
| 02/03/2005 | CA2531492A1 Compositions for purifying and crystallizing molecules of interest |
| 02/03/2005 | CA2530357A1 Sustained release dosage forms of anesthetics for pain management |
| 02/03/2005 | CA2530285A1 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 02/03/2005 | CA2529405A1 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| 02/03/2005 | CA2524184A1 Microbial cellulose wound dressing comprising phmb |
| 02/03/2005 | CA2499307A1 Treatment of heaves using r-(-)albuterol |
| 02/02/2005 | EP1502644A2 Combination of emulsifiers, emulsion containing the same and process for preparing the same. |
| 02/02/2005 | EP1502595A1 An injection made from ixeris sonchifolia for treatment of cardio-cerebral vascular disease and fundus diseases and method of producing thereof |
| 02/02/2005 | EP1502592A1 Controlled release oxycodone compositions |
| 02/02/2005 | EP1502591A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 02/02/2005 | EP1502589A1 Veterinary aqueous injectable suspensions containing florfenicol |
| 02/02/2005 | EP1502020A2 Stackable low depth tray |
| 02/02/2005 | EP1501918A1 Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| 02/02/2005 | EP1501861A1 Targeting proteins to deliver therapeutic or diagnostic reagents |
| 02/02/2005 | EP1501860A2 Modulation of heat-shock-protein-based immunotherapies |
| 02/02/2005 | EP1501853A2 RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/02/2005 | EP1501806A1 Preparations for the topical application of anti-androgenically active substances |
| 02/02/2005 | EP1501774A1 Polyunsaturated linear aldehydes and their derivatives with anti-radical and anti-tumoral activity |
| 02/02/2005 | EP1501551A1 Vitamin-targeted imaging agents |
| 02/02/2005 | EP1501550A1 Non-viral gene delivery system |
| 02/02/2005 | EP1501549A2 Lyophilised and liquid preparations comprising a polysaccharide derivative of camptothecin |
| 02/02/2005 | EP1501541A1 Encapsulated cells to elicit immune responses |
| 02/02/2005 | EP1501522A2 Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents |
| 02/02/2005 | EP1501502A2 Carvedilol pharmasolve solvate |
| 02/02/2005 | EP1501501A2 Method for oxygen treatment of unsaturated carbon compounds, novel epoxy-structured material obtained by the method, apparatus for carrying out the method and a therapeutic composition using the material |
| 02/02/2005 | EP1501500A2 Carvedilol formulations |
| 02/02/2005 | EP1501499A1 Trans-epicutaneous administration form for treating restless leg syndrome |
| 02/02/2005 | EP1501497A2 Catechin multimers as therapeutic drug delivery agents |
| 02/02/2005 | EP1501496A2 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| 02/02/2005 | EP1501487A1 Capsule preparation |
| 02/02/2005 | EP1501485A1 High drug load tablet |
| 02/02/2005 | EP1501482A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
| 02/02/2005 | EP1501481A2 Dispersions of lipids for use as therapeutic and cosmetic agents and intracellular delivery vehicles |
| 02/02/2005 | EP1501480A1 Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs |
| 02/02/2005 | EP1501479A1 Capsules for dry powder inhalers and methods of making and using same |
| 02/02/2005 | EP1501478A1 Warming and nonirritating anhydrous lubricant compositions |
| 02/02/2005 | EP1501357A2 Use of vegf for treating bone defects |
| 02/02/2005 | EP1501352A1 Methods and compositions for controlled release of drugs |
| 02/02/2005 | EP1404334A4 Targeted delivery of bioaffecting compounds for the treatment of cancer |
| 02/02/2005 | EP1379257A4 Prodrugs of anticancer agents employing substituted aromatic acids |
| 02/02/2005 | EP1351980A4 Peptides for activation and inhibition of delta pkc |
| 02/02/2005 | EP1235574B1 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 02/02/2005 | EP1218009B1 Quetiapine granules |
| 02/02/2005 | EP1175390B1 Disodium salts, monohydrates, and ethanol solvates |
| 02/02/2005 | EP1135166B9 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 02/02/2005 | EP1131104B1 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |